A couple of years ago, Dendreon sold off a manufacturing plant to Novartis for $40 million-plus to raise some quick cash.
Someone can pick up its two remaining manufacturing facilities, a logistics center and headquarters in Seattle and its one-time promising drug, Provenge, for as little as $275 million.